Appropriate scenarios for discussing Ozempic with your healthcare provider include: You have type 2 diabetes and PCOS , and standard treatments have not adequately controlled your blood glucose or metabolic symptoms You have significant obesity alongside PCOS and have not achieved sufficient weight loss through lifestyle measures and metformin (note that Wegovy, not Ozempic, is the licensed semaglutide product for weight management through specialist NHS weight management services) You are experiencing insulin resistance confirmed through blood tests, and first-line treatments have been insufficient Your GP will need to assess several factors before considering Ozempic: Current medications and potential drug interactions Medical history , particularly thyroid disease, pancreatitis, gallbladder disease, or diabetic retinopathy Treatment goals and whether Ozempic aligns with evidence-based management Important safety considerations to discuss include: Common gastrointestinal side effects and how to manage them Risk of hypoglycaemia if used with sulfonylureas or insulin The need for regular monitoring of blood glucose, kidney function, and weight Pregnancy planning, as semaglutide should be discontinued at least 2 months before conception and is not recommended during breastfeeding [1] Symptoms of pancreatitis (severe abdominal pain) or gallbladder disease that require prompt medical attention Potential worsening of diabetic retinopathy in those with pre-existing disease It is vital to understand that Ozempic is not a substitute for established PCOS treatments and should not be viewed as a direct treatment for ovarian cysts themselves
Mild side effects may include nausea, bloating, or stomach discomfort in some users
Medical Reference Guide: Animation Pages: Kidney Stones
See how much Weight You can Lose Explore Patients Success Stories Use our online Price Calculator Start your weight loss journey today I had been stuck at the same weight for years and nothing seemed to work
These findings suggest that NRF2 has a protective role in psoriasis and that SFN enhances NRF2 and p-NRF2 expression
Rosaly believes that Semaglutide is a powerful tool, but its success is maximized when paired with professional clinical oversight and personalized education
